申请人:Smith P. Craig
公开号:US20070129403A1
公开(公告)日:2007-06-07
The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula I
wherein in is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1;
each R is independently hydrogen, halogen, trifluoromethyl, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, benzyloxy, hydroxy, nitro or amino;
each R
1
is independently hydrogen, C
1
-C
6
alkyl, C
1
-C
6
alkenyl,
C
1
-C
6
alkanoyl, halogen, cyano, —C(O)C
1
-C
6
alkyl, —C
1
-C
6
alkyleneCN, —C
1
-C
6
alkyleneNR′R″ wherein R′ and R″ are each independently hydrogen or C
1
-C
6
alkyl, —C
1
-C
6
alkyleneOC(O)C
1
-C
6
alkyl, or —CH(OH)R
4
wherein R
4
is hydrogen or C
1
-C
6
alkyl;
R
2
is hydrogen, C
1
-C
6
alkyl optionally substituted with halogen, hydroxy or benlzyloxy, C
1
-C
6
alkenyl, C
1
-C
6
alkynyl, —CO
2
C
1
-C
6
alkyl, or —R
5
—NR′R″ wherein R
5
is C
1
-C
6
alkylene, C
1
-C
6
alkenylene or C
1
-C
6
alkynylene and R′ and R″ are each independently hydrogen, C
1
-C
6
alkyl or alternatively the group —NR′R″ as a whole is 1-pyrrolidinyl; and
R
3
is hydrogen, nitro, amino, halogen, C
1
-C
6
alkoxy, hydroxy or C
1
-C
6
alkyl or a pharmaceutically acceptable salt thereof.